Novavax’s vaccine is at the moment in mid-stage trials (Representational)
U.S. drug developer Novavax mentioned on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capability to 2 billion doses yearly beneath an settlement with Serum Institute of India, sending its shares up about 7%.
In August, Novavax signed a take care of Serum Institute, the world’s largest producer of vaccines, to supply a minimal of 1 billion doses of its vaccine candidate, when permitted, for low and middle-income international locations and India.
As a part of the expanded settlement, Serum Institute may also manufacture the antigen part of the vaccine, dubbed NVX-CoV2373, which Novavax mentioned will deliver its manufacturing capability to over two billion doses by mid-2021.
Novavax’s vaccine is at the moment in mid-stage trials after an early-stage research confirmed it produced excessive ranges of antibodies in opposition to the novel coronavirus. The corporate plans to start late-stage trials within the third quarter.
Final month, Novavax mentioned it should provide 60 million doses of its coronavirus vaccine candidate to the UK starting as early as the primary quarter of 2021.
The corporate can also be getting ready to ship 100 million doses to the USA by January after it was awarded $1.6 billion for its potential vaccine, and has additionally signed provide agreements with Canada and Japan.
Different drugmakers akin to Pfizer and Moderna have already begun giant late-stage research of their experimental vaccines.
(Aside from the headline, this story has not been edited by NDTV employees and is printed from a syndicated feed.)
Source link
